Skip to main navigation Skip to main content
info(at)avldigital.remove-this.de
Deutsch English
Narrow Search
Search narrowed by
Last searches

Results for *

Displaying results 1 to 5 of 5.

  1. Zombie-Journalismus
    Was kommt nach dem Tod der Meinungsfreiheit?
    Author: Klöckner, Marcus B.
    Published: 2021
    Publisher:  Rubikon, Mainz

    Export to reference management software   RIS file
      BibTeX file
  2. Thérapie Génique:une technologie bouleversant le marché pharmaceutique
    Etude de cas: LogicBio Therapeutics
    Author: Dorier-Sammut, Diane
    Published: 2020
    Publisher:  Éditions universitaires européennes, Saarbrücken

    Export to reference management software   RIS file
      BibTeX file
  3. Der Kult
    Über die Viralität des Bösen
    Author: Kaiser, Gunnar
    Published: 2022
    Publisher:  Rubikon, München

    Location:
    Staatliche Bibliothek, Provinzialbibliothek
    Inter-library loan:
    Unlimited inter-library loan, copies and loan

    Location:
    Hochschule für Fernsehen und Film, Bibliothek
    Inter-library loan:
    No loan of volumes, only paper copies will be sent

    Location:
    Universitätsbibliothek Würzburg
    Inter-library loan:
    Unlimited inter-library loan, copies and loan
    Export to reference management software   RIS file
      BibTeX file
  4. Patents for Covid-19 vaccines are based on public research: a case study on the privatization of knowledge
    Author: Florio, Massimo
    Published: [2021]
    Publisher:  CIRIEC International, Université de Liège, Liège (Belgium)

    Access:
    Verlag (kostenfrei)
    Resolving-System (kostenfrei)
    Resolving-System (kostenfrei)

    Location:
    ZBW - Leibniz-Informationszentrum Wirtschaft, Standort Kiel
    Signature:
    ZSS 2
    Inter-library loan:
    No inter-library loan
    Export to reference management software   RIS file
      BibTeX file
    Source: Union catalogues
    Language: English
    Media type: Ebook
    Format: Online
    ISBN: 9782931051504
    Other identifier:
    hdl: 11159/6416
    Edition: This version October 11, 2021
    Series: Working paper / CIRIEC ; no. 2021, 03
    Subjects: COVID 19 pandemic; vaccines; public and private R&D; Big Pharma; public funding; USA
    Scope: 1 Online-Ressource (circa 32 Seiten), Illustrationen
  5. The TRIPS waiver proposal: an urgent measure to expand access to the COVID-19 vaccines
    Author: Menezes, Henrique Zeferino de
    Published: 2021
    Publisher:  South Centre, Geneva

    Despite multilateral commitments and political statements of solidarity and cooperation to guarantee the availability and access to COVID-19 vaccines (and other relevant technologies for control and treatment), the scenario after the beginning of... more

    Access:
    Verlag (kostenfrei)
    Verlag (kostenfrei)
    Resolving-System (kostenfrei)

    Location:
    ZBW - Leibniz-Informationszentrum Wirtschaft, Standort Kiel
    Signature:
    DS 751
    Inter-library loan:
    No inter-library loan

     

    Despite multilateral commitments and political statements of solidarity and cooperation to guarantee the availability and access to COVID-19 vaccines (and other relevant technologies for control and treatment), the scenario after the beginning of vaccination is marked by the deepening of vaccine nationalism, the concentration of inputs and vaccines production, and the uneven distribution of options of vaccine doses already approved for use. This pattern of production restrictions and unequal access will lead to an increase in international inequalities, leaving a large part of the world to have access to vaccines not until 2024. While advanced purchase agreements (APAs) among pharmaceutical companies and some developed countries are multiplying, the proposed mechanisms for voluntary licensing of technologies and the COVAX Facility do not achieve their goal of democratizing access to vaccines. In this sense, the current TRIPS (Agreement on Trade-Related Aspects of Intellectual Property Rights) waiver proposal seems to be the political and institutional response with the greatest potential to guarantee the scaling of the production of pharmaceutical inputs, allowing the adoption of a comprehensive strategy to ensure timely, sufficient, and affordable access to all technologies developed to fight COVID-19.

     
    Export to reference management software   RIS file
      BibTeX file